Serum anti-GM-CSF autoantibody levels, unlike levels in bronchoalveolar fluid, do not correlate with disease severity in patients with autoimmune PAP [22, 23]. Here, CSF2 is linked to autoimmune pulmonary alveolar proteinosis.